Jolein Gyonne Elise Laumen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Jolein Gyonne Elise Laumen has a total of 85 co-authors. Here are the top co-authors by number of shared publications:
- Chris Kenyon
Department of Clinical Sciences, Institute of Tropical Medicine, Antwerp, Belgium
19 shared publications - Sheeba Santhini Manoharan-Basil
Department of Clinical Sciences, Institute of Tropical Medicine, Antwerp, Belgium
19 shared publications - Christophe Van Dijck
Department of Clinical Sciences, Institute of Tropical Medicine, Antwerp, Belgium
16 shared publications - Saïd Abdellati
Clinical and Reference Laboratory, Department of Clinical Sciences, Institute of Tropical Medicine, 2000 Antwerp, Belgium
12 shared publications - Irith De Baetselier
Institute of Tropical Medicine
11 shared publications Irith De Baetselier
Clinical Reference Laboratory, Department of Clinical Sciences, Institute of Tropical Medicine, Antwerp, Antwerp, 2000, Belgium
8 shared publications
Latest Publications
- Open Access
- 17 August 2026
- Published by Microbiology Society
Introduction of Fluroquinolone-Resistant Salmonella enterica serovar Typhi Strains into Cambodia: A Phylogenomic Analysis
Salmonella enterica subspecies enterica serovar Typhi (S. Typhi) is a Gram-negative bacterium responsible for typhoid fever, a significant public health concern in low- and middle-income countries, where it primarily affects children and young adults. Effective treatment relies on antimicrobial therapy; however, the emergence of antimicrobial resistance, particularly to fluoroquinolones like ciprofloxacin, has complicated management strategies. This study focuses on two ciprofloxacin-resistant S. Typhi strains isolated in January 2017 from two Indian nationals in Phnom Penh, Cambodia, marking the first documented cases of ciprofloxacin-resistant S. Typhi in the country. Through whole-genome sequencing, we aimed to determine whether these strains represented a newly imported clone or a reemergence of an endemic strain with increased resistance. Phenotypic antimicrobial susceptibility testing confirmed that both isolates were resistant to ciprofloxacin while susceptible to other tested antibiotics, including azithromycin and ceftriaxone, the current first-line treatments in regions with high ciprofloxacin resistance. Genomic analysis revealed that both strains harbored three resistance-conferring mutations gyrA-S83F, gyrA_D87N, and parC_S80I. Phylogenomic comparison of these strains with global S. Typhi datasets identified them as part of the genotype 4.3.1.2.1, a recently designated sub-lineage associated with fluoroquinolone resistance. The strains clustered closely with S. Typhi isolates from India, suggesting that they were likely imported from India rather than representing local evolution. This study reveals the likely introduction of the ciprofloxacin-resistant genotype 4.3.1.2.1 into Cambodia and underscores the importance of targeted genomic surveillance in tracking the spread of antimicrobial resistance in S. Typhi. Although the introduction of ciprofloxacin-resistant strains probably poses minimal additional threat in Cambodia, where fluoroquinolone non-susceptibility is already widespread, the potential for the spread of more resistant variants, such as those carrying ceftriaxone resistance, underscores the need for robust surveillance and the eventual adoption of typhoid vaccines in endemic regions. The study also illustrates the growing potential for LMICs to integrate whole genome sequencing into their antimicrobial resistance surveillance programs as the technology becomes more accessible, thereby enhancing public health responses to typhoid fever.
- 17 August 2026
- Published by Microbiology Society
Open AccessIntroduction of Fluroquinolone-Resistant Salmonella enterica serovar Typhi Strains into Cambodia: A Phylogenomic Analysis
Salmonella enterica subspecies enterica serovar Typhi (S. Typhi) is a Gram-negative bacterium responsible for typhoid fever, a significant public health concern in low- and middle-income countries, where it primarily affects children and young adults. Effective treatment relies on antimicrobial therapy; however, the emergence of antimicrobial resistance, particularly to fluoroquinolones like ciprofloxacin, has complicated management strategies. This study focuses on two ciprofloxacin-resistant S. Typhi strains isolated in January 2017 from two Indian nationals in Phnom Penh, Cambodia, marking the first documented cases of ciprofloxacin-resistant S. Typhi in the country. Through whole-genome sequencing, we aimed to determine whether these strains represented a newly imported clone or a reemergence of an endemic strain with increased resistance. Phenotypic antimicrobial susceptibility testing confirmed that both isolates were resistant to ciprofloxacin while susceptible to other tested antibiotics, including azithromycin and ceftriaxone, the current first-line treatments in regions with high ciprofloxacin resistance. Genomic analysis revealed that both strains harbored three resistance-conferring mutations gyrA-S83F, gyrA_D87N, and parC_S80I. Phylogenomic comparison of these strains with global S. Typhi datasets identified them as part of the genotype 4.3.1.2.1, a recently designated sub-lineage associated with fluoroquinolone resistance. The strains clustered closely with S. Typhi isolates from India, suggesting that they were likely imported from India rather than representing local evolution. This study reveals the likely introduction of the ciprofloxacin-resistant genotype 4.3.1.2.1 into Cambodia and underscores the importance of targeted genomic surveillance in tracking the spread of antimicrobial resistance in S. Typhi. Although the introduction of ciprofloxacin-resistant strains probably poses minimal additional threat in Cambodia, where fluoroquinolone non-susceptibility is already widespread, the potential for the spread of more resistant variants, such as those carrying ceftriaxone resistance, underscores the need for robust surveillance and the eventual adoption of typhoid vaccines in endemic regions. The study also illustrates the growing potential for LMICs to integrate whole genome sequencing into their antimicrobial resistance surveillance programs as the technology becomes more accessible, thereby enhancing public health responses to typhoid fever.
- Open Access
- 12 February 2025
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
- Vol. 232 (1) , e73-e77
High Prevalence of Ceftriaxone-Resistant Neisseria gonorrhoeae in Hanoi, Vietnam, 2023–2024
Ceftriaxone resistance in Neisseria gonorrhoeae is an escalating global health concern, threatening the efficacy of empiric treatment. In the Asia-Pacific region, a rapid surge in ceftriaxone resistance has been observed, primarily associated with the penA-60.001 allele. This study, conducted in Hanoi, Vietnam between 2023 and 2024, analyzed 352 N. gonorrhoeae isolates and found a 27% prevalence of ceftriaxone resistance. Whole-genome sequencing identified that resistance was predominantly driven by the mosaic penA-237.001 allele, with a smaller contribution from penA-60.001. The high prevalence of resistance and the emergence of new alleles underscore the urgent threat to ceftriaxone as an empiric treatment option.
- 12 February 2025
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
- Vol. 232 (1) , e73-e77
Open AccessHigh Prevalence of Ceftriaxone-Resistant Neisseria gonorrhoeae in Hanoi, Vietnam, 2023–2024
Ceftriaxone resistance in Neisseria gonorrhoeae is an escalating global health concern, threatening the efficacy of empiric treatment. In the Asia-Pacific region, a rapid surge in ceftriaxone resistance has been observed, primarily associated with the penA-60.001 allele. This study, conducted in Hanoi, Vietnam between 2023 and 2024, analyzed 352 N. gonorrhoeae isolates and found a 27% prevalence of ceftriaxone resistance. Whole-genome sequencing identified that resistance was predominantly driven by the mosaic penA-237.001 allele, with a smaller contribution from penA-60.001. The high prevalence of resistance and the emergence of new alleles underscore the urgent threat to ceftriaxone as an empiric treatment option.
- Open Access
- 4 December 2023
- Published by Springer Nature in Research Square
The effect of daily usage of Listerine Cool Mint mouthwash on the oropharyngeal microbiome
Listerine is a bactericidal mouthwash used to prevent oral health problems such as dental plaque and gingivitis. It is unknown whether it promotes or undermines a healthy oral microbiome. We aimed to assess if daily usage of Listerine Cool Mint® influenced the composition of the pharyngeal microbiome. The current microbiome substudy is part of the PreGo trial conducted in 2019-2020, wherein sixty-four MSM taking HIV PrEP were enrolled. In this crossover trial, participants were received 3 months of daily Listerine followed by 3 months of placebo mouthwash or vice versa. Oropharyngeal swabs were taken at baseline and after 3 months use of each mouthwash. DNA was extracted for shotgun metagenomic sequencing (Illumina Inc.,). Non-host reads were taxonomically classified with MiniKraken and Bracken. The diversity indices alpha and beta diversity were compared between baseline and after each mouthwash use. Differentially abundant bacterial taxa were identified using ANOVA-Like Differential Expression analysis. Streptococcus was the most abundant genus in most samples (n=103, 61.7%) with a median relative abundance of 31.5% [IQR 20.6 to 44.8], followed by Prevotella (13.5%, [IQR 4.8 to 22.6]) and Veillonella (10.0%, [IQR 4.0 to 16.8]). Compared to baseline, the composition of the oral microbiome at the genus level (beta diversity) was significantly different after 3 months Listerine (P=0.006, pseudo-F = 2.29) or placebo (P=0.003, pseudo-F = 2.49, PERMANOVA) use. Fusobacterium nucleatum and Streptococcus anginosus were significantly more abundant after Listerine use compared to baseline. Listerine use was associated with an increased abundance of common oral opportunistic bacteria previously reported to be enriched in periodontal diseases, oesophageal and colorectal cancer, and systemic diseases. These findings suggest that the applications of Listerine mouthwash should be carefully considered.
- 4 December 2023
- Published by Springer Nature in Research Square
Open AccessThe effect of daily usage of Listerine Cool Mint mouthwash on the oropharyngeal microbiome
Listerine is a bactericidal mouthwash used to prevent oral health problems such as dental plaque and gingivitis. It is unknown whether it promotes or undermines a healthy oral microbiome. We aimed to assess if daily usage of Listerine Cool Mint® influenced the composition of the pharyngeal microbiome. The current microbiome substudy is part of the PreGo trial conducted in 2019-2020, wherein sixty-four MSM taking HIV PrEP were enrolled. In this crossover trial, participants were received 3 months of daily Listerine followed by 3 months of placebo mouthwash or vice versa. Oropharyngeal swabs were taken at baseline and after 3 months use of each mouthwash. DNA was extracted for shotgun metagenomic sequencing (Illumina Inc.,). Non-host reads were taxonomically classified with MiniKraken and Bracken. The diversity indices alpha and beta diversity were compared between baseline and after each mouthwash use. Differentially abundant bacterial taxa were identified using ANOVA-Like Differential Expression analysis. Streptococcus was the most abundant genus in most samples (n=103, 61.7%) with a median relative abundance of 31.5% [IQR 20.6 to 44.8], followed by Prevotella (13.5%, [IQR 4.8 to 22.6]) and Veillonella (10.0%, [IQR 4.0 to 16.8]). Compared to baseline, the composition of the oral microbiome at the genus level (beta diversity) was significantly different after 3 months Listerine (P=0.006, pseudo-F = 2.29) or placebo (P=0.003, pseudo-F = 2.49, PERMANOVA) use. Fusobacterium nucleatum and Streptococcus anginosus were significantly more abundant after Listerine use compared to baseline. Listerine use was associated with an increased abundance of common oral opportunistic bacteria previously reported to be enriched in periodontal diseases, oesophageal and colorectal cancer, and systemic diseases. These findings suggest that the applications of Listerine mouthwash should be carefully considered.
- Open Access
- 8 September 2023
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 10 (10) , ofad462
Effect on the Resistome of Dual vs Monotherapy for the Treatment of Neisseria gonorrhoeae: Results From a Randomized Controlled Trial (ResistAZM Trial)
No randomized controlled trial (RCT) has compared the impact on the resistome of ceftriaxone (CRO) plus azithromycin (AZM) vs CRO for the treatment of Neisseria gonorrhoea (NG). This was an open-label, single-center, RCT comparing the effect on the resistome of CRO plus AZM vs CRO for the treatment of NG. Men who have sex with men (MSM) with genital, anorectal, or pharyngeal NG infection were randomized into the CRO/AZM and CRO arms. Oral rinse and anorectal samples were taken for culture and resistome profiling at 2 visits (baseline and day 14). The primary outcome was the ratio of mean macrolide resistance determinants in anorectal samples from day 14 between arms. Twenty individuals were randomized into the CRO/AZM arm and 22 into the CRO arm. We found no significant difference in the mean macrolide resistance determinants in the day 14 anorectal samples between arms (ratio, 1.05; 95% CI, 0.55–1.83; P = .102). The prevalence of baseline macrolide resistance was high (CRO/AZM arm = 95.00%; CRO arm = 90.91%). We could not demonstrate a significant effect of dual CRO/AZM therapy on the resistome compared with CRO alone, likely due to a high baseline resistance to AZM. Interventions to prevent the emergence of antimicrobial resistance in MSM are needed.
- 8 September 2023
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 10 (10) , ofad462
Open AccessEffect on the Resistome of Dual vs Monotherapy for the Treatment of Neisseria gonorrhoeae: Results From a Randomized Controlled Trial (ResistAZM Trial)
No randomized controlled trial (RCT) has compared the impact on the resistome of ceftriaxone (CRO) plus azithromycin (AZM) vs CRO for the treatment of Neisseria gonorrhoea (NG). This was an open-label, single-center, RCT comparing the effect on the resistome of CRO plus AZM vs CRO for the treatment of NG. Men who have sex with men (MSM) with genital, anorectal, or pharyngeal NG infection were randomized into the CRO/AZM and CRO arms. Oral rinse and anorectal samples were taken for culture and resistome profiling at 2 visits (baseline and day 14). The primary outcome was the ratio of mean macrolide resistance determinants in anorectal samples from day 14 between arms. Twenty individuals were randomized into the CRO/AZM arm and 22 into the CRO arm. We found no significant difference in the mean macrolide resistance determinants in the day 14 anorectal samples between arms (ratio, 1.05; 95% CI, 0.55–1.83; P = .102). The prevalence of baseline macrolide resistance was high (CRO/AZM arm = 95.00%; CRO arm = 90.91%). We could not demonstrate a significant effect of dual CRO/AZM therapy on the resistome compared with CRO alone, likely due to a high baseline resistance to AZM. Interventions to prevent the emergence of antimicrobial resistance in MSM are needed.
- 9 February 2023
- Published by Elsevier in Journal of Infection
- Vol. 86 (4) , 329-337
The oropharynx of men using HIV pre-exposure prophylaxis is enriched with antibiotic resistance genes: A cross-sectional observational metagenomic study
- 9 February 2023
- Published by Elsevier in Journal of Infection
- Vol. 86 (4) , 329-337
The oropharynx of men using HIV pre-exposure prophylaxis is enriched with antibiotic resistance genes: A cross-sectional observational metagenomic study
- Open Access
- 27 January 2023
- Published by F1000 Research Ltd in F1000Research
- Vol. 11, 1464
Pre-exposure to azithromycin enhances gonococcal resilience to subsequent ciprofloxacin exposure: an in vitro study
Background: The effect of sequential exposure to different antibiotics is an underexplored topic. Azithromycin can be detected in humans for up to 28 days post-ingestion and may prime bacterial responses to subsequently ingested antibiotics. Methods: In this in vitro study, we assessed if preexposure to azithromycin could accelerate the acquisition of resistance to ciprofloxacin in Neisseria gonorrhoeae reference strain, WHO–F. In a morbidostat, we set two conditions in 3 vials each: mono-exposure (preexposure to Gonococcal Broth followed by exposure to ciprofloxacin) and dual sequential exposure (preexposure to azithromycin followed by exposure to ciprofloxacin).The growth of the cultures was measured by a software (MATLAB). The program decided if gonococcal broth or antibiotics were added to the vials in order to keep the evolution of the cultures. Samples were taken twice a week until the end of the experiment i.e. until resistance was achieved or cellular death. Additionally, six replicates of WHO–F WT and WHO–F with rplV mutation, caused by azithromycin, were exposed to increasing concentrations of ciprofloxacin in plates to assess if there were differences in the rate of resistance emergence. Results: We found that after 12 hours of pre-exposure to azithromycin, N. gonorrhoeae's resilience to ciprofloxacin exposure increased. Pre-exposure to azithromycin did not, however, accelerate the speed to acquisition of ciprofloxacin resistance. Conclusions: We found that azithromycin does not accelerate the emergence of ciprofloxacin resistance, but there were differences in the molecular pathways to the acquisition of ciprofloxacin resistance: the strains preexpossed to azithromycin followed a different route (GyrA: S91F pathway) than the ones without antibiotic preexposure (GyrA:D95N pathway). However, the number of isolates is too small to draw such strong conclusions.
- 27 January 2023
- Published by F1000 Research Ltd in F1000Research
- Vol. 11, 1464
Open AccessPre-exposure to azithromycin enhances gonococcal resilience to subsequent ciprofloxacin exposure: an in vitro study
Background: The effect of sequential exposure to different antibiotics is an underexplored topic. Azithromycin can be detected in humans for up to 28 days post-ingestion and may prime bacterial responses to subsequently ingested antibiotics. Methods: In this in vitro study, we assessed if preexposure to azithromycin could accelerate the acquisition of resistance to ciprofloxacin in Neisseria gonorrhoeae reference strain, WHO–F. In a morbidostat, we set two conditions in 3 vials each: mono-exposure (preexposure to Gonococcal Broth followed by exposure to ciprofloxacin) and dual sequential exposure (preexposure to azithromycin followed by exposure to ciprofloxacin).The growth of the cultures was measured by a software (MATLAB). The program decided if gonococcal broth or antibiotics were added to the vials in order to keep the evolution of the cultures. Samples were taken twice a week until the end of the experiment i.e. until resistance was achieved or cellular death. Additionally, six replicates of WHO–F WT and WHO–F with rplV mutation, caused by azithromycin, were exposed to increasing concentrations of ciprofloxacin in plates to assess if there were differences in the rate of resistance emergence. Results: We found that after 12 hours of pre-exposure to azithromycin, N. gonorrhoeae's resilience to ciprofloxacin exposure increased. Pre-exposure to azithromycin did not, however, accelerate the speed to acquisition of ciprofloxacin resistance. Conclusions: We found that azithromycin does not accelerate the emergence of ciprofloxacin resistance, but there were differences in the molecular pathways to the acquisition of ciprofloxacin resistance: the strains preexpossed to azithromycin followed a different route (GyrA: S91F pathway) than the ones without antibiotic preexposure (GyrA:D95N pathway). However, the number of isolates is too small to draw such strong conclusions.
- Open Access
- 16 December 2022
- Published by MDPI AG in Microorganisms
- Vol. 10 (12) , 2497
The Discovery of Oropharyngeal Microbiota with Inhibitory Activity against Pathogenic Neisseria gonorrhoeae and Neisseria meningitidis: An In Vitro Study of Clinical Isolates
With increasing incidence of pathogenic Neisseria infections coupled with emerging resistance to antimicrobials, alternative approaches to limit the spread are sought. We investigated the inhibitory effect of oropharyngeal microbiota on the growth of N. gonorrhoeae and N. meningitidis and the impact of the essential oil-based mouthwash Listerine Cool Mint® (Listerine). Oropharyngeal swabs from 64 men who have sex with men (n = 118) from a previous study (PReGo study) were analysed (ClinicalTrials.gov, NCT03881007). These included 64 baseline and 54 samples following three months of daily use of Listerine. Inhibition was confirmed by agar overlay assay, and inhibitory bacteria isolated using replica plating and identified using MALDI-TOF. The number of inhibitory isolates were compared before and after Listerine use. Thirty-one pharyngeal samples (26%) showed inhibitory activity against N. gonorrhoeae and/or N. meningitidis, and 62 inhibitory isolates were characterised. Fourteen species belonging to the genera Streptococci and Rothia were identified. More inhibitory isolates were observed following Listerine use compared to baseline, although this effect was not statistically significant (p = 0.073). This study isolated and identified inhibitory bacteria against pathogenic Neisseria spp. and established that daily Listerine use did not decrease their prevalence. These findings could provide a new approach for the prevention and treatment of pharyngeal Neisseria infections.
- 16 December 2022
- Published by MDPI AG in Microorganisms
- Vol. 10 (12) , 2497
Open AccessThe Discovery of Oropharyngeal Microbiota with Inhibitory Activity against Pathogenic Neisseria gonorrhoeae and Neisseria meningitidis: An In Vitro Study of Clinical Isolates
With increasing incidence of pathogenic Neisseria infections coupled with emerging resistance to antimicrobials, alternative approaches to limit the spread are sought. We investigated the inhibitory effect of oropharyngeal microbiota on the growth of N. gonorrhoeae and N. meningitidis and the impact of the essential oil-based mouthwash Listerine Cool Mint® (Listerine). Oropharyngeal swabs from 64 men who have sex with men (n = 118) from a previous study (PReGo study) were analysed (ClinicalTrials.gov, NCT03881007). These included 64 baseline and 54 samples following three months of daily use of Listerine. Inhibition was confirmed by agar overlay assay, and inhibitory bacteria isolated using replica plating and identified using MALDI-TOF. The number of inhibitory isolates were compared before and after Listerine use. Thirty-one pharyngeal samples (26%) showed inhibitory activity against N. gonorrhoeae and/or N. meningitidis, and 62 inhibitory isolates were characterised. Fourteen species belonging to the genera Streptococci and Rothia were identified. More inhibitory isolates were observed following Listerine use compared to baseline, although this effect was not statistically significant (p = 0.073). This study isolated and identified inhibitory bacteria against pathogenic Neisseria spp. and established that daily Listerine use did not decrease their prevalence. These findings could provide a new approach for the prevention and treatment of pharyngeal Neisseria infections.
- Open Access
- 9 December 2022
- Published by F1000 Research Ltd in F1000Research
- Vol. 11, 1464
Pre-exposure to azithromycin enhances gonococcal resilience to subsequent ciprofloxacin exposure: an in vitro study
Background: The effect of sequential exposure to different antibiotics is an underexplored topic. Azithromycin can be detected in humans for up to 28 days post-ingestion and may prime bacterial responses to subsequently ingested antibiotics. Methods: In this in vitro study, we assessed if preexposure to azithromycin could accelerate the acquisition of resistance to ciprofloxacin in Neisseria gonorrhoeae reference strain, WHO–F. In a morbidostat, we set two conditions in 3 vials each: mono-exposure (preexposure to Gonococcal Broth followed by exposure to ciprofloxacin) and dual sequential exposure (preexposure to azithromycin followed by exposure to ciprofloxacin).The growth of the cultures was measured by a software (MATLAB). The program decided if gonococcal broth or antibiotics were added to the vials in order to keep the evolution of the cultures. Samples were taken twice a week until the end of the experiment i.e. until resistance was achieved or cellular death. Additionally, six replicates of WHO–F WT and WHO–F with rplV mutation, caused by azithromycin, were exposed to increasing concentrations of ciprofloxacin in plates to assess if there were differences in the rate of resistance emergence. Results: We found that after 12 hours of pre-exposure to azithromycin, N. gonorrhoeae's resilience to ciprofloxacin exposure increased. Pre-exposure to azithromycin did not, however, accelerate the speed to acquisition of ciprofloxacin resistance. Conclusions: We found that azithromycin does not accelerate the emergence of ciprofloxacin resistance, but there were differences in the molecular pathways to the acquisition of ciprofloxacin resistance: the strains preexpossed to azithromycin followed a different route (GyrA: S91F pathway) than the ones without antibiotic preexposure (GyrA:D95N pathway). However, the number of isolates is too small to draw such strong conclusions.
- 9 December 2022
- Published by F1000 Research Ltd in F1000Research
- Vol. 11, 1464
Open AccessPre-exposure to azithromycin enhances gonococcal resilience to subsequent ciprofloxacin exposure: an in vitro study
Background: The effect of sequential exposure to different antibiotics is an underexplored topic. Azithromycin can be detected in humans for up to 28 days post-ingestion and may prime bacterial responses to subsequently ingested antibiotics. Methods: In this in vitro study, we assessed if preexposure to azithromycin could accelerate the acquisition of resistance to ciprofloxacin in Neisseria gonorrhoeae reference strain, WHO–F. In a morbidostat, we set two conditions in 3 vials each: mono-exposure (preexposure to Gonococcal Broth followed by exposure to ciprofloxacin) and dual sequential exposure (preexposure to azithromycin followed by exposure to ciprofloxacin).The growth of the cultures was measured by a software (MATLAB). The program decided if gonococcal broth or antibiotics were added to the vials in order to keep the evolution of the cultures. Samples were taken twice a week until the end of the experiment i.e. until resistance was achieved or cellular death. Additionally, six replicates of WHO–F WT and WHO–F with rplV mutation, caused by azithromycin, were exposed to increasing concentrations of ciprofloxacin in plates to assess if there were differences in the rate of resistance emergence. Results: We found that after 12 hours of pre-exposure to azithromycin, N. gonorrhoeae's resilience to ciprofloxacin exposure increased. Pre-exposure to azithromycin did not, however, accelerate the speed to acquisition of ciprofloxacin resistance. Conclusions: We found that azithromycin does not accelerate the emergence of ciprofloxacin resistance, but there were differences in the molecular pathways to the acquisition of ciprofloxacin resistance: the strains preexpossed to azithromycin followed a different route (GyrA: S91F pathway) than the ones without antibiotic preexposure (GyrA:D95N pathway). However, the number of isolates is too small to draw such strong conclusions.
- Open Access
- 26 October 2022
- Published by MDPI AG in Antibiotics
- Vol. 11 (11) , 1480
Tolerance to Ceftriaxone in Neisseria gonorrhoeae: Rapid Induction in WHO P Reference Strain and Detection in Clinical Isolates
In addition to antimicrobial resistance, bacteria contain other mechanisms to survive antibiotic exposure such as tolerance, defined as the ability to slow metabolism by the extension of the lag phase without altering antimicrobial susceptibility. In a number of bacterial species, tolerance has been associated with treatment failure and infection chronicity and is found to precede and facilitate antimicrobial resistance. It is unknown if tolerance can be induced in Neisseria gonorrhoeae. In this study, we determined if tolerance to ceftriaxone (CRO) can be induced in N. gonorrhoeae and detected in clinical isolates. To induce tolerance, WHO P N. gonorrhoeae reference strain samples were grown under daily 3 h intermittent CRO exposure (10× the MIC), partitioned by overnight growth in GC broth. This cyclic exposure was performed for 7 consecutive days in sextuplicate, with two control cultures to which GC medium without antibiotics was added. To detect tolerance and assess CRO susceptibility, modified Tolerance Disc (TD) and Epsilometer tests were performed on isolates after each CRO exposure cycle. Additionally, this experiment was carried out on 18 clinical N. gonorrhoeae isolates. Tolerance was first detected after two CRO exposure cycles in five out of six samples. The phenotype differed per cycle with no clear pattern. No tolerance was found in control samples but was detected in 10 out of 18 clinical isolates. The present study is the first to demonstrate the induction of tolerance to CRO in N. gonorrhoeae through antibiotic exposure. In addition, tolerance to CRO was found in clinical samples.
- 26 October 2022
- Published by MDPI AG in Antibiotics
- Vol. 11 (11) , 1480
Open AccessTolerance to Ceftriaxone in Neisseria gonorrhoeae: Rapid Induction in WHO P Reference Strain and Detection in Clinical Isolates
In addition to antimicrobial resistance, bacteria contain other mechanisms to survive antibiotic exposure such as tolerance, defined as the ability to slow metabolism by the extension of the lag phase without altering antimicrobial susceptibility. In a number of bacterial species, tolerance has been associated with treatment failure and infection chronicity and is found to precede and facilitate antimicrobial resistance. It is unknown if tolerance can be induced in Neisseria gonorrhoeae. In this study, we determined if tolerance to ceftriaxone (CRO) can be induced in N. gonorrhoeae and detected in clinical isolates. To induce tolerance, WHO P N. gonorrhoeae reference strain samples were grown under daily 3 h intermittent CRO exposure (10× the MIC), partitioned by overnight growth in GC broth. This cyclic exposure was performed for 7 consecutive days in sextuplicate, with two control cultures to which GC medium without antibiotics was added. To detect tolerance and assess CRO susceptibility, modified Tolerance Disc (TD) and Epsilometer tests were performed on isolates after each CRO exposure cycle. Additionally, this experiment was carried out on 18 clinical N. gonorrhoeae isolates. Tolerance was first detected after two CRO exposure cycles in five out of six samples. The phenotype differed per cycle with no clear pattern. No tolerance was found in control samples but was detected in 10 out of 18 clinical isolates. The present study is the first to demonstrate the induction of tolerance to CRO in N. gonorrhoeae through antibiotic exposure. In addition, tolerance to CRO was found in clinical samples.
- Open Access
- 18 October 2022
- Published by MDPI AG in Antibiotics
- Vol. 11 (10) , 1430
Ciprofloxacin Concentrations 1/1000th the MIC Can Select for Antimicrobial Resistance in N. gonorrhoeae—Important Implications for Maximum Residue Limits in Food
Background: Concentrations of fluoroquinolones up to 200-fold lower than the minimal inhibitory concentration (MIC) have been shown to be able to select for antimicrobial resistance in E. coli and Salmonella spp. (the minimum selection concentration—MSC). We hypothesized that the low concentrations of quinolones found in meat may play a role in the genesis of quinolone resistance in Neisseria gonorrhoeae. We aimed to (i) establish the ciprofloxacin MSC for N. gonorrhoeae and (ii) assess if, at the ecological level, the prevalence of gonococcal ciprofloxacin resistance is associated with the concentration of quinolones used in food animal production, which is an important determinant of long-term low-dose exposure to ciprofloxacin in humans. Methods: (i) To assess if subinhibitory ciprofloxacin concentrations could select for de novo generated resistant mutants, a susceptible WHO-P N. gonorrhoeae isolate was serially passaged at 1, 1:10, 1:100 and 1:1000 of the ciprofloxacin MIC of WHO-P (0.004 mg/L) on GC agar plates. (ii) Spearman’s correlation was used to assess the association between the prevalence of ciprofloxacin resistance in N. gonorrhoeae and quinolone use for animals and quinolone consumption by humans. Results: Ciprofloxacin concentrations as low as 0.004 µg/L (1/1000 of the MIC of WHO-P) were able to select for ciprofloxacin resistance. The prevalence of ciprofloxacin resistance in N. gonorrhoeae was positively associated with quinolone use for food animals (ρ = 0.47; p = 0.004; N = 34). Conclusion: Further individual level research is required to assess if low doses of ciprofloxacin from ingested foodstuffs are able to select for ciprofloxacin resistance in bacteria colonizing humans and other species.
- 18 October 2022
- Published by MDPI AG in Antibiotics
- Vol. 11 (10) , 1430
Open AccessCiprofloxacin Concentrations 1/1000th the MIC Can Select for Antimicrobial Resistance in N. gonorrhoeae—Important Implications for Maximum Residue Limits in Food
Background: Concentrations of fluoroquinolones up to 200-fold lower than the minimal inhibitory concentration (MIC) have been shown to be able to select for antimicrobial resistance in E. coli and Salmonella spp. (the minimum selection concentration—MSC). We hypothesized that the low concentrations of quinolones found in meat may play a role in the genesis of quinolone resistance in Neisseria gonorrhoeae. We aimed to (i) establish the ciprofloxacin MSC for N. gonorrhoeae and (ii) assess if, at the ecological level, the prevalence of gonococcal ciprofloxacin resistance is associated with the concentration of quinolones used in food animal production, which is an important determinant of long-term low-dose exposure to ciprofloxacin in humans. Methods: (i) To assess if subinhibitory ciprofloxacin concentrations could select for de novo generated resistant mutants, a susceptible WHO-P N. gonorrhoeae isolate was serially passaged at 1, 1:10, 1:100 and 1:1000 of the ciprofloxacin MIC of WHO-P (0.004 mg/L) on GC agar plates. (ii) Spearman’s correlation was used to assess the association between the prevalence of ciprofloxacin resistance in N. gonorrhoeae and quinolone use for animals and quinolone consumption by humans. Results: Ciprofloxacin concentrations as low as 0.004 µg/L (1/1000 of the MIC of WHO-P) were able to select for ciprofloxacin resistance. The prevalence of ciprofloxacin resistance in N. gonorrhoeae was positively associated with quinolone use for food animals (ρ = 0.47; p = 0.004; N = 34). Conclusion: Further individual level research is required to assess if low doses of ciprofloxacin from ingested foodstuffs are able to select for ciprofloxacin resistance in bacteria colonizing humans and other species.